Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $750.00 Price Target at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price decreased by Citigroup from $795.00 to $750.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Citigroup currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on the company. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $686.33 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals has a 1 year low of $666.25 and a 1 year high of $1,211.20. The firm has a 50-day moving average of $725.65 and a 200 day moving average of $933.22. The company has a market cap of $75.42 billion, a P/E ratio of 16.98, a PEG ratio of 1.59 and a beta of 0.10.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Creative Planning grew its position in Regeneron Pharmaceuticals by 11.5% in the 2nd quarter. Creative Planning now owns 9,615 shares of the biopharmaceutical company’s stock worth $10,106,000 after purchasing an additional 991 shares during the period. Magnolia Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $236,000. NewEdge Advisors LLC increased its position in Regeneron Pharmaceuticals by 6.3% during the second quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company’s stock valued at $4,591,000 after acquiring an additional 260 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Regeneron Pharmaceuticals by 16.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock valued at $4,016,000 after acquiring an additional 536 shares during the period. Finally, B. Riley Wealth Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 8.0% in the second quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock worth $1,142,000 after purchasing an additional 80 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.